China's Health Reform Will Nurture New Drugs, While Boosting Use Of Old Ones - PharmAsia Summit

SAN FRANCISCO - In addition to dramatically increasing access to mainly generic drugs, China's sweeping and upcoming health reform will also include measures designed to spur R&D, according to Song Ruilin, Executive Director-General at the Chinese Pharmaceutical Association's Research Center for Medicinal Policy